Mark Kirschbaum
2023
In 2023, Mark Kirschbaum earned a total compensation of $480.6K as Former Senior Vice President and Chief Medical Officer at Cyclacel Pharmaceuticals, a 8% decrease compared to previous year.
Compensation breakdown
| Option Awards | $31,003 |
|---|---|
| Salary | $396,760 |
| Other | $52,855 |
| Total | $480,618 |
Kirschbaum received $396.8K in salary, accounting for 83% of the total pay in 2023.
Kirschbaum also received $31K in option awards and $52.9K in other compensation.
Rankings
In 2023, Mark Kirschbaum's compensation ranked 1,916th out of 2,647 executives tracked by ExecPay. In other words, Kirschbaum earned more than 27.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,916 out of 2,647 | 28th |
Division Manufacturing | 1,090 out of 1,447 | 25th |
Major group Chemicals And Allied Products | 669 out of 817 | 18th |
Industry group Drugs | 652 out of 783 | 17th |
Industry Pharmaceutical Preparations | 461 out of 555 | 17th |
Source: SEC filing on May 7, 2024.
Kirschbaum's colleagues
We found two more compensation records of executives who worked with Mark Kirschbaum at Cyclacel Pharmaceuticals in 2023.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021